EXEL · NASDAQ · Healthcare · $17.2B· Short % 15.1%
$69.39+4.8%vs prev closeclose of 2026-10-30 · not real-time
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who…· Source: company profile (yfinance/Yahoo Finance)
💰 Net stock buybacks last fiscal year: $947.5M · 5.51% of market cap
vs. analyst consensus target. The target is an opinion, not a prediction or buy signal.
A summary of valuation factors — not a buy recommendation. You decide.
| Company | PER | PBR | ROE | Div | Score |
|---|---|---|---|---|---|
| Exelixis Inc. | 21.9 | 8.4 | 44% | 0.0% | 62 |
| Charles River Laboratories International Inc. | – | 6.0 | -8% | 0.0% | 28 |
| Revvity Inc. | 75.1 | 2.4 | 3% | 0.2% | 30 |
| Ascendis Pharma A/S | 19.3 | 10.2 | 119% | 0.0% | 45 |
| Zimmer Biomet Holdings Inc. | 22.9 | 1.4 | 6% | 1.0% | 57 |
| Medpace Holdings Inc. | 36.2 | 31.2 | 118% | 0.0% | 49 |
Same sector, nearest by market cap · – = no data (value traps excluded)
Chart patterns matched (observational)
Technical patterns for reference — not a buy recommendation.
The chart (long-term trend, Ichimoku cloud) is for observation only — not a buy or sell signal.
Shows only where the current price sits within the channel structure (based on past swings).
The channel, levels and gaps are observational geometry showing where the current price sits within past swing structure. They are not a rebound/bottom probability, a price target, or a buy/sell signal — plain chart patterns carry no reliable predictive edge (our backtest conclusion).
A highlight of the key metrics detailed below.
Undervalued vs sector 40/100 within Healthcare — higher means lower multiples (PER·PB·EV/EBITDA·PSR) than sector peers. Growth sectors carry higher multiples, so this is a same-sector relative view, not absolute cheapness (observational).
PER vs its own history PER is in the bottom 35% of its own 8-year range (historically cheap)Range 11.8–44.4 · median 19.1Observational only — a lower PER can reflect slowing growth, so 'cheap' isn't always undervalued.
Top-tier in 2 of 7 evaluated strategies
Ranks within the US market — tap to open that ranking (ranks are per market).
Past returns — they do not guarantee future results.
EV as reported by our data provider (Yahoo Finance) · net debt is our own calc (total debt − cash) · definitions differ, so EV need not equal market cap + net debt (minority interest, preferred stock)
Color: green = healthy, red = caution (absolute thresholds, value/quality metrics only). Downside vol & Sortino are annualized. Max drawdown = largest drop from a 3-year peak; volatility = 1-year annualized. Price/Graham < 1 = below Graham fair value (profitable, positive-equity names only). RSI < 30 = oversold. For reference only.
A Japanese trend tool. Price above the 'cloud' is supportive; below is weak. A strong uptrend doesn't mean it's cheap — stocks that have run up are usually more expensive.